Impax Generics

Generic SupplementsGeneric Supplement 2016

Impax Generics is the multiple-source products division of Impax Laboratories, Inc.


Impax Generics is the multiple-source products division of Impax Laboratories, Inc. Last year, Impax completed the acquisition of Tower Holdings, Inc (Tower) and combined 2 operating subsidiaries of Tower—CorePharma, LLC, and Lineage Therapeutics, Inc—with Global Pharmaceuticals to form the Impax Generics division. In doing so, we increased our commercial portfolio of products, broadened our research and development efforts, strengthened our generic pipeline, and expanded and diversified our manufacturing, packaging, and supply-chain capabilities.


Impax Generics continues to focus on the development, manufacture, and commercialization of complex generic pharmaceutical products, as well as identifying complementary business opportunities. Our core competencies include expertise in controlled-release products, controlled substances, and other difficult-to-formulate products. Using our controlledrelease drug delivery technologies and formulation skills, we develop bioequivalent versions of selected brand name pharmaceuticals, many of which have technically challenging drug delivery requirements.

We bring value to our customers with innovative products in key therapeutic areas. We currently market 55 generic pharmaceutical products. The newest products in our portfolio include methyltestosterone 10-mg capsules (equivalent to Testred® [methyltestosterone]), dutasteride 0.5-mg capsules (equivalent to Avodart® [dutasteride]), and pyridostigmine bromide 180-mg tablets (equivalent to Mestinon® [pyridostigmine bromide]).a


The generic pipeline consists of 25 products with Abbreviated New Drug Applications pending FDA approval, 12 of which are either confirmed or potential first-to-file or first-to-market opportunities.a We also have a number of products in various stages of development. Our pipeline is well diversified with a mix of solid-oral and alternative dosage—form products across a broad range of therapeutic areas.


Our mission is to ensure the availability of high-quality, affordable generic pharmaceuticals and bring value to our customers while conducting our business with uncompromising integrity and ethics.

aData as of February 26, 2016.

For more information, visit

Recent Videos
Practice Pearl #1 Active Surveillance vs Treatment in Patients with NETs